These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. King KE; Shirey RS; Lankiewicz MW; Young-Ramsaran J; Ness PM Transfusion; 1997 Apr; 37(4):376-81. PubMed ID: 9111274 [TBL] [Abstract][Full Text] [Related]
30. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Aygun B; Padmanabhan S; Paley C; Chandrasekaran V Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310 [TBL] [Abstract][Full Text] [Related]
31. A delayed hemolytic transfusion reaction after partial exchange transfusion for sickle cell disease in pregnancy: a case report and review of the literature. Brumfield CG; Huddleston JF; DuBois LB; Harris BA Obstet Gynecol; 1984 Mar; 63(3 Suppl):13S-15S. PubMed ID: 6700873 [TBL] [Abstract][Full Text] [Related]
32. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Cullis JO; Win N; Dudley JM; Kaye T Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307 [TBL] [Abstract][Full Text] [Related]
33. Posttransfusion crises in sickle cell anemia: role of delayed hemolytic reactions to transfusion. Milner PF; Squires JE; Larison PJ; Charles WT; Krauss JS South Med J; 1985 Dec; 78(12):1462-9. PubMed ID: 4071176 [TBL] [Abstract][Full Text] [Related]
34. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. Chonat S; Chandrakasan S; Kalinyak KA; Ingala D; Gruppo R; Kalfa TA Br J Haematol; 2016 Nov; 175(4):744-747. PubMed ID: 27870017 [No Abstract] [Full Text] [Related]
35. [Risks associated with transfusions in sickle cell disease: delayed hemolytic transfusion reaction]. Habibi A; Noizat-Pirenne F Rev Prat; 2014 Oct; 64(8):1128-9. PubMed ID: 25510142 [No Abstract] [Full Text] [Related]
36. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far. Meenan J; Hall R; Badle S; Chatterjee B; Win N; Tsitsikas DA Transfusion; 2022 Mar; 62(3):546-550. PubMed ID: 35092617 [TBL] [Abstract][Full Text] [Related]
37. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. Moog P; Jost PJ; Büttner-Herold M BMC Nephrol; 2018 May; 19(1):106. PubMed ID: 29724174 [TBL] [Abstract][Full Text] [Related]
38. Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia. Buchanan GR; Bowman WP; Smith SJ J Pediatr; 1983 Dec; 103(6):921-3. PubMed ID: 6644427 [No Abstract] [Full Text] [Related]
39. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079 [TBL] [Abstract][Full Text] [Related]